Free Trial
→ Official Black Friday Sale Is Live (Trading Indicator) (From Base Camp Trading) (Ad)tc pixel
NASDAQ:KTTA

Pasithea Therapeutics Q3 2026 Earnings Date & Estimates

Pasithea Therapeutics logo
$0.53 -0.01 (-2.64%)
As of 12:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pasithea Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Pasithea Therapeutics in Q3 2026

Pasithea Therapeutics is expected to post earnings of -$0.21 per share on revenue of $200 thousand. In the same quarter a year earlier Pasithea Therapeutics reported -$0.41 per share. Pasithea Therapeutics last reported on August 14, 2026, posting -$0.16 per share and matching the -$0.16 consensus estimate.

Consensus Estimates

Consensus EPS
-$0.21
Expected Revenue
$200 thousand
Prior-Year EPS
-$0.41

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.16 (Met Expectations)

Prepare for the Q3 2026 Call

Pasithea Therapeutics Q3 2026 Earnings FAQ

Pasithea Therapeutics (NASDAQ:KTTA) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Pasithea Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Pasithea Therapeutics to post earnings of -$0.21 per share for Q3 2026.

The consensus revenue estimate for Pasithea Therapeutics is $200 thousand for Q3 2026.

Pasithea Therapeutics Earnings Headlines

Pasithea Therapeutics (KTTA) Set to Announce Quarterly Earnings on Thursday
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179419
Pasithea Therapeutics (NASDAQ:KTTA) Stock Crosses Above Fifty Day Moving Average - Here's Why
November 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31178293
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
KTTA - Pasithea Therapeutics Corp.
November 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/KTTA/balance-sheet
FDA Clears Pasithea's PAS-004 IND For Phase 2 Study In NF1-Related Skin Tumors; Stock Up
November 3, 2026  |  rttnews.comhttps://www.rttnews.com/3707868/fda-clears-pasithea-s-pas-004-ind-for-phase-2-study-in-nf1-related-skin-tumors-stock-up.aspx
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
November 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/03/3394061/0/en/pasithea-therapeutics-announces-fda-clearance-of-ind-for-pas-004-in-neurofibromatosis-type-1-nf1-associated-cutaneous-neurofibromas-cnf.html
See More Pasithea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pasithea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pasithea Therapeutics and other key companies, straight to your email.

About Pasithea Therapeutics

Pasithea Therapeutics (NASDAQ:KTTA) is a biotechnology company focused on developing treatments for central nervous system (CNS) disorders. Its research has centered on novel therapies for conditions such as depression and other neuropsychiatric diseases, areas in which existing treatments may not provide adequate results for all patients.

The company has also pursued psychedelic-based therapeutic approaches and related clinical-development programs. In addition to drug discovery, Pasithea has explored treatment-delivery activities, including ketamine-assisted therapy services through operations associated with its business. Its programs and strategy have evolved as the company evaluates opportunities in CNS therapeutics and related areas of unmet medical need.

Pasithea Therapeutics is headquartered in the United States and has had business activities connected with both U.S. and international markets, including the United Kingdom. The company’s common stock trades on the Nasdaq Capital Market under the symbol KTTA.

View Pasithea Therapeutics Profile
Earnings Tools